5月14日,诺和诺德公司宣布,其与美国生物技术公司Septerna达成了一项合作与许可协议,将共同开发治疗肥胖症、2型糖尿病和其他心血管疾病的口服小分子药物。诺和诺德表示,Septerna公司将有资格获得约22亿美元的收益,其中包括超2亿美元的前期和近期付款。
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.